Ameriprise Financial Inc. Makes New $789,000 Investment in Enliven Therapeutics, Inc. (NASDAQ:ELVN)

Ameriprise Financial Inc. acquired a new stake in Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 35,059 shares of the company's stock, valued at approximately $789,000. Ameriprise Financial Inc. owned 0.07% of Enliven Therapeutics as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. Tower Research Capital LLC TRC lifted its holdings in shares of Enliven Therapeutics by 230.2% in the fourth quarter. Tower Research Capital LLC TRC now owns 1,598 shares of the company's stock valued at $36,000 after buying an additional 1,114 shares during the period. KLP Kapitalforvaltning AS acquired a new stake in shares of Enliven Therapeutics in the fourth quarter valued at $97,000. ExodusPoint Capital Management LP acquired a new stake in shares of Enliven Therapeutics in the fourth quarter valued at $200,000. China Universal Asset Management Co. Ltd. lifted its holdings in shares of Enliven Therapeutics by 14.0% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 10,360 shares of the company's stock valued at $233,000 after buying an additional 1,275 shares during the period. Finally, Price T Rowe Associates Inc. MD lifted its holdings in shares of Enliven Therapeutics by 17.0% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 13,627 shares of the company's stock valued at $307,000 after buying an additional 1,980 shares during the period. Institutional investors and hedge funds own 95.08% of the company's stock.

Analyst Upgrades and Downgrades

ELVN has been the subject of several research analyst reports. Jones Trading cut their price objective on Enliven Therapeutics from $36.00 to $27.00 and set a "buy" rating for the company in a report on Friday, May 16th. HC Wainwright upped their price objective on Enliven Therapeutics from $39.00 to $40.00 and gave the company a "buy" rating in a report on Thursday, May 15th. Four analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Enliven Therapeutics has a consensus rating of "Buy" and a consensus target price of $37.25.

Enliven Therapeutics Stock Down 2.9%

Shares of NASDAQ ELVN traded down $0.63 during mid-day trading on Friday, hitting $20.74. 663,450 shares of the company traded hands, compared to its average volume of 269,810. Enliven Therapeutics, Inc. has a 1 year low of $13.30 and a 1 year high of $30.03. The stock has a market capitalization of $1.02 billion, a price-to-earnings ratio of -10.92 and a beta of 1.07. The business has a 50 day moving average of $18.05 and a two-hundred day moving average of $20.85.

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last announced its earnings results on Wednesday, May 14th. The company reported ($0.57) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.06). As a group, research analysts anticipate that Enliven Therapeutics, Inc. will post -1.95 EPS for the current year.

Insider Activity

In related news, CEO Samuel Kintz sold 12,500 shares of the stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $20.83, for a total value of $260,375.00. Following the completion of the sale, the chief executive officer now directly owns 990,392 shares of the company's stock, valued at approximately $20,629,865.36. This represents a 1.25% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Benjamin Hohl sold 3,250 shares of the stock in a transaction dated Thursday, March 27th. The stock was sold at an average price of $21.33, for a total value of $69,322.50. Following the completion of the sale, the chief financial officer now directly owns 23,000 shares of the company's stock, valued at approximately $490,590. This represents a 12.38% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 94,444 shares of company stock valued at $1,801,057 over the last three months. Insiders own 29.20% of the company's stock.

Enliven Therapeutics Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.